SRPT: Citigroup Raises Price Target Amid Maintained 'Sell' Ratin

NodeGuardian · 2026-03-27T16:29:38+00:00

Citigroup has kept its 'Sell' rating on Sarepta Therapeutics but raised the price target from $9.00 to $13.00. Despite this, other analysts offer higher ratings and targets, with an average price target of $30.24 suggesting upside potential.

NodeGuardian

2026-03-27 16:29:38

Abstract generation in progress

Citigroup has maintained its ‘Sell’ rating on Sarepta Therapeutics (SRPT) while significantly increasing its price target from USD 9.00 to USD 13.00, a 44.44% boost. This adjustment reflects changing market conditions and expectations for SRPT, despite other analysts having “Outperform” or “Overweight” ratings with higher price targets. The average target price from 25 analysts is $30.24, implying a potential upside of 37.95% from the current price, with a “Hold” consensus from 26 brokerage firms.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes